SureNano Science Accelerates Development of Obesity Drug Candidate GEP-44 with IND-Enabling Studies

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has initiated a Good Laboratory Practice (GLP) toxicology and pharmacology program for its lead drug candidate GEP-44, a multi-receptor peptide designed to treat obesity and type 2 diabetes. This program aligns with U.S. Food and Drug Administration (FDA) requirements and is intended to support an Investigational New Drug (IND) application, a necessary step before first-in-human clinical trials.

The company is positioning itself as an agile entrant in the rapidly expanding GLP-1 market, having secured licensing rights to GEP-44 from Syracuse University. The compound is a patented high-performing second-generation incretin-based therapy that offers improved tolerability and potential for non-injectable delivery, according to the company's announcement. Dr. Nihar Pandey, Chief Scientific Officer at SureNano, emphasized that initiating these FDA IND-enabling studies is a major milestone for the company and its subsidiary GlucaPharm. “Partnering with a globally renowned CRO like LabCorp will ensure our studies meet the highest regulatory standards,” said Dr. Pandey. “This package is vital to de-risk our lead candidate and is designed to support our strategy of launching a Phase I clinical trial in Australia.”

The announcement follows SureNano's acquisition of GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company. SureNano initially operated through the sale of its SureNano(TM) surfactant, a food-grade compound for nanoemulsions, but is now pivoting to become a pharmaceutical-focused company. The company has exclusive licenses to distribute the surfactant in parts of Canada and the United States.

The obesity and type 2 diabetes market is large and growing, with GLP-1 receptor agonists becoming blockbuster drugs. GEP-44, as a multi-receptor peptide, aims to offer advantages over existing therapies, potentially including better tolerability and non-injectable formulations. The initiation of GLP studies is a critical step in de-risking the candidate and moving toward clinical evaluation. For more details, view the full article at https://ibn.fm/78hI3.

SureNano Science is a Canadian life sciences company focused on acquiring and advancing innovative pharmaceutical and biotechnology assets. Through its subsidiary GlucaPharm, it is developing GEP44 to address obesity and metabolic disorders. The company's shift from surfactant distribution to pharmaceutical development marks a strategic transformation aimed at capturing value in the metabolic disease space. For ongoing updates, visit the company's newsroom at https://ibn.fm/SURNF.